stoxline Quote Chart Rank Option Currency Glossary
Verona Pharma plc (VRNA)
15.84  -0.82 (-4.92%)    06-18 12:14
Open: 16.71
High: 16.96
Volume: 418,203
Pre. Close: 16.66
Low: 15.77
Market Cap: 1,284(M)
Technical analysis
2024-06-18 11:54:08 AM
Short term     
Mid term     
Targets 6-month :  19.85 1-year :  23.19
Resists First :  17 Second :  19.85
Pivot price 13.33
Supports First :  13.53 Second :  11.39
MAs MA(5) :  15.66 MA(20) :  13.08
MA(100) :  15.58 MA(250) :  16.64
MACD MACD :  0.4 Signal :  -0.2
%K %D K(14,3) :  82.1 D(3) :  79.8
RSI RSI(14): 67.8
52-week High :  23.06 Low :  11.39
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VRNA ] has closed below upper band by 8.8%. Bollinger Bands are 179.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 17.02 - 17.09 17.09 - 17.15
Low: 14.97 - 15.05 15.05 - 15.11
Close: 16.52 - 16.65 16.65 - 16.77
Company Description

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Headline News

Tue, 18 Jun 2024
Verona Pharma plc's (NASDAQ:VRNA) Path To Profitability - Simply Wall St

Sun, 16 Jun 2024
Perceptive Advisors LLC Sells 140,983 Shares of Verona Pharma plc (NASDAQ:VRNA) - MarketBeat

Sat, 15 Jun 2024
Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know - Yahoo New Zealand News

Sat, 15 Jun 2024
Trend Tracker for (VRNA) - Stock Traders Daily

Sat, 15 Jun 2024
Verona Pharma (NASDAQ:VRNA) Sees Strong Trading Volume - Defense World

Thu, 13 Jun 2024
Parkman Healthcare Partners LLC Grows Stock Position in Verona Pharma plc (NASDAQ:VRNA) - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 81 (M)
Shares Float 470 (M)
Held by Insiders 3.9 (%)
Held by Institutions 88 (%)
Shares Short 5,570 (K)
Shares Short P.Month 6,070 (K)
Stock Financials
EPS -0.81
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.77
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -15 %
Return on Equity (ttm) -25.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.9
Qtrly Earnings Growth 0 %
Operating Cash Flow -58 (M)
Levered Free Cash Flow -42 (M)
Stock Valuations
PE Ratio -20.25
PEG Ratio 0
Price to Book value 5.82
Price to Sales 0
Price to Cash Flow -22.63
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android